This is in line with previous findings in breast cancer [30], but in contrast with the study in non-small cell lung cancer by Lohr et al., wherein high immune cell-specific CD138 expression was found to correlate with improved patient outcome [9]. This evidence concerns the gene SDC1 and breast carcinoma.